Do angiogenesis inhibitors perform a physiologic gatekeeper role in cancer prevention?
Libutti
Steven K
SK
Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. slibutti@nih.gov
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D019700:Thrombospondin 1 / Q000502:physiology
D020533:Angiogenesis Inhibitors; D019700:Thrombospondin 1